View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 23, 2020updated 12 Jul 2022 11:44am

Gilead to test inhaled version of remdesivir for Covid-19

Gilead Sciences has received approval from the US Food and Drug Administration (FDA) to assess an inhaled version of remdesivir in human clinical trials as a potential treatment for Covid-19 patients.

Gilead Sciences has received approval from the US Food and Drug Administration (FDA) to assess an inhaled version of remdesivir in human clinical trials as a potential treatment for Covid-19 patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The company will start screening healthy participants for Phase I trials this week, with plans to initiate trials in Covid-19 patients in August.

Currently, the drug is administered intravenously in the hospital. An inhaled version of remdesivir can be given using a nebulizer, potentially enabling easier administration outside the hospital and at earlier stages of infection.

The company also intends to assess intravenous infusions in outpatient settings, including infusion centres and nursing homes. This earlier intervention is expected to particularly help patients at high risk of disease progression and avoid hospitalisation.

In an open letter, Gilead chairman and CEO Daniel O’Day said: “Based on our knowledge of the disease so far, it seems that in the earlier stages of Covid-19, the virus itself is the primary driver of illness. In the later stages, the body’s inflammatory response may cause some of the most life-threatening aspects of the disease.

“It is important, therefore, to have tools that can work together to fight both aspects of the disease: an antiviral to target the virus itself and another therapy to tackle the inflammatory response.”

The company is also set to explore the use of remdesivir as a combination therapy, including with anti-inflammatory agents, for treating severely ill patients.

Gilead will study the drug in combination with with two immune modulators, baricitinib and tocilizumab, over the coming months.

Furthermore, studies are being planned to involve vulnerable patient populations.

In addition to the Phase II/III trial being conducted in paediatric patients hospitalised with Covid-19, the company is planning studies in pregnant women and patients with end-stage renal disease.

Gilead is working to manufacture more than two million treatment courses of remdesivir by the end of this year and millions more by next year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena